Review



cd63  (Miltenyi Biotec)


Bioz Verified Symbol Miltenyi Biotec is a verified supplier
Bioz Manufacturer Symbol Miltenyi Biotec manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 93

    Structured Review

    Miltenyi Biotec cd63
    Cd63, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 93/100, based on 16 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mouse+anti+cd63/CD63+Antibody%2C+anti-mouse%2C+REAfinity/pm42023517-55-16-17
    Average 93 stars, based on 16 article reviews
    cd63 - by Bioz Stars, 2026-09
    93/100 stars

    Images

    Related Articles

    Electron Microscopy:

    Article Title: CNS-derived extracellular vesicles from superoxide dismutase 1 (SOD1)G93A ALS mice originate from astrocytes and neurons and carry misfolded SOD1
    Article Snippet: All grids were negatively stained with 0.5% aqueous uranyl acetate for 30 s, and viewed on a FEI Tecnai G2 Spirit Transmission Electron Microscope. .. Antibodies were purchased from: mouse anti-CD63 (Clone H5C6) and mouse antiSNAP25 both from BioLegend; mouse anti-GLAST (Clone ACSA-1) and hamster anti-CD81-biotinylated (Clone EAT2) both from Miltenyi; guinea pig anti-VGAT (Synaptic Systems, Goettingen Germany); all secondary antibodies (anti-mouse 15nm gold, antibiotin-25nm gold, anti-guinea pig-10 nm gold) purchased from Electron Microscopy Sciences. ..

    Incubation:

    Article Title: The P2X4 purinergic receptor controls the autophagy-related release of small extracellular vesicles from mammary cancer cells under hypoxia.
    Article Snippet: The proportion of CD9-, CD63- and CD81-positive subpopulations of EVs were estimated from same samples by Fluo-NTA (Zetaview PMX120, Particle Metrix). .. Briefly, primary antibodies coupled with phycoerythrine (PE) were incubated for 2 h at room temperature: mouse anti-CD9 (1: 6, ref. 130-123-052 Miltenyi Biotec, France), mouse anti-CD63 (1: 10, ref. 130-108-923 Miltenyi Biotec, France) and mouse anti-CD81 (1: 10, ref. 130-102-632 Miltenyi Biotec, France). ..

    Article Title: The P2X4 purinergic receptor controls the autophagy-related release of small extracellular vesicles from mammary cancer cells under hypoxia
    Article Snippet: The proportion of CD9-, CD63- and CD81-positive subpopulations of EVs were estimated from same samples by Fluo-NTA (Zetaview PMX-120, Particle Metrix). .. Briefly, primary antibodies coupled with phycoerythrine (PE) were incubated for 2 h at room temperature: mouse anti-CD9 (1: 6, ref. 130-123-052 Miltenyi Biotec, France), mouse anti-CD63 (1: 10, ref. 130-108-923 Miltenyi Biotec, France) and mouse anti-CD81 (1: 10, ref. 130-102-632 Miltenyi Biotec, France). ..



    Similar Products

    93
    Miltenyi Biotec cd63
    Cd63, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mouse+anti+cd63/CD63+Antibody%2C+anti-mouse%2C+REAfinity/pm42023517-55-16-17
    Average 93 stars, based on 1 article reviews
    cd63 - by Bioz Stars, 2026-09
    93/100 stars
      Buy from Supplier

    93
    Bio-Rad anti cd63
    Anti Cd63, supplied by Bio-Rad, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mouse+anti+cd63/Mouse+anti+Bovine+CD63/pmc13137739-102-6-9
    Average 93 stars, based on 1 article reviews
    anti cd63 - by Bioz Stars, 2026-09
    93/100 stars
      Buy from Supplier

    95
    Novus Biologicals cd63 h5c6 mouse mab novus biologicals
    Cd63 H5c6 Mouse Mab Novus Biologicals, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mouse+anti+cd63/CD63+Antibody+(H5C6)+-+BSA+Free/pm41974939-163-34-38
    Average 95 stars, based on 1 article reviews
    cd63 h5c6 mouse mab novus biologicals - by Bioz Stars, 2026-09
    95/100 stars
      Buy from Supplier

    93
    Bio-Rad mouse anti bovine cd63
    Mouse Anti Bovine Cd63, supplied by Bio-Rad, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mouse+anti+cd63/Mouse+anti+Bovine+CD63/pm41937065-76-24-29
    Average 93 stars, based on 1 article reviews
    mouse anti bovine cd63 - by Bioz Stars, 2026-09
    93/100 stars
      Buy from Supplier

    93
    Bio-Rad mca2142 rrid ab 324562
    Mca2142 Rrid Ab 324562, supplied by Bio-Rad, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mouse+anti+cd63/Mouse+anti+Human+CD63/pmc12993400-26-4-2
    Average 93 stars, based on 1 article reviews
    mca2142 rrid ab 324562 - by Bioz Stars, 2026-09
    93/100 stars
      Buy from Supplier

    93
    Bio-Rad cd63
    Characterization of plasma EV in MI patients EVs were isolated from the plasma of MI patients at hospital presentation and at 3-month follow-up. (A) EV-Array analysis of canonical EV-associated markers shows significant enrichment at MI presentation ( n = 17 patients paired at both timepoints). (B) EV-cell-associated markers were also enriched at presentation with MI. White in the heatmaps denotes the baseline (normalized to 1), corresponding to the 3-month follow-up value. (C) Total EV concentrations measured by NTA of SEC and ultracentrifugation-purified plasma EVs. (D and E) Spaghetti plots showing EV size and particle concentration profiles at the individual patient level across the two timepoints ( n = 19 patients paired at both timepoints). (E) Western blotting confirmed the presence of EV markers (CD9 and Syntenin-1), absence of cellular contaminants (GM130, ATP5A, and Histone H3), and depletion of the plasma Apo B. (F) TEM images confirmed typical cup-shaped EV morphology. Scale bars, 500 nm or 100 nm. (G and H) Single-particle interferometric reflectance imaging (NanoView) confirmed tetraspanin-positive EVs (CD9, <t>CD63,</t> and CD81), (H) with associated size and concentration profiles ( n = 9–10 at both timepoints). EV marker values at MI presentation were normalized to each patient’s own 3-month follow-up value. In (G), data are presented as group means ± SD. Statistical analysis: (A–C) Wilcoxon matched-pairs signed-rank test; (G) two-way ANOVA with Tukey’s post hoc test. ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001.
    Cd63, supplied by Bio-Rad, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mouse+anti+cd63/Mouse+anti+Human+CD63/pmc12993400-26-0-2
    Average 93 stars, based on 1 article reviews
    cd63 - by Bioz Stars, 2026-09
    93/100 stars
      Buy from Supplier

    95
    Miltenyi Biotec mouse anti cd63
    Characterization of plasma EV in MI patients EVs were isolated from the plasma of MI patients at hospital presentation and at 3-month follow-up. (A) EV-Array analysis of canonical EV-associated markers shows significant enrichment at MI presentation ( n = 17 patients paired at both timepoints). (B) EV-cell-associated markers were also enriched at presentation with MI. White in the heatmaps denotes the baseline (normalized to 1), corresponding to the 3-month follow-up value. (C) Total EV concentrations measured by NTA of SEC and ultracentrifugation-purified plasma EVs. (D and E) Spaghetti plots showing EV size and particle concentration profiles at the individual patient level across the two timepoints ( n = 19 patients paired at both timepoints). (E) Western blotting confirmed the presence of EV markers (CD9 and Syntenin-1), absence of cellular contaminants (GM130, ATP5A, and Histone H3), and depletion of the plasma Apo B. (F) TEM images confirmed typical cup-shaped EV morphology. Scale bars, 500 nm or 100 nm. (G and H) Single-particle interferometric reflectance imaging (NanoView) confirmed tetraspanin-positive EVs (CD9, <t>CD63,</t> and CD81), (H) with associated size and concentration profiles ( n = 9–10 at both timepoints). EV marker values at MI presentation were normalized to each patient’s own 3-month follow-up value. In (G), data are presented as group means ± SD. Statistical analysis: (A–C) Wilcoxon matched-pairs signed-rank test; (G) two-way ANOVA with Tukey’s post hoc test. ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001.
    Mouse Anti Cd63, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mouse+anti+cd63/CD63+Antibody%2C+anti-human/pmc13101154-133-24-30
    Average 95 stars, based on 1 article reviews
    mouse anti cd63 - by Bioz Stars, 2026-09
    95/100 stars
      Buy from Supplier

    Image Search Results


    Characterization of plasma EV in MI patients EVs were isolated from the plasma of MI patients at hospital presentation and at 3-month follow-up. (A) EV-Array analysis of canonical EV-associated markers shows significant enrichment at MI presentation ( n = 17 patients paired at both timepoints). (B) EV-cell-associated markers were also enriched at presentation with MI. White in the heatmaps denotes the baseline (normalized to 1), corresponding to the 3-month follow-up value. (C) Total EV concentrations measured by NTA of SEC and ultracentrifugation-purified plasma EVs. (D and E) Spaghetti plots showing EV size and particle concentration profiles at the individual patient level across the two timepoints ( n = 19 patients paired at both timepoints). (E) Western blotting confirmed the presence of EV markers (CD9 and Syntenin-1), absence of cellular contaminants (GM130, ATP5A, and Histone H3), and depletion of the plasma Apo B. (F) TEM images confirmed typical cup-shaped EV morphology. Scale bars, 500 nm or 100 nm. (G and H) Single-particle interferometric reflectance imaging (NanoView) confirmed tetraspanin-positive EVs (CD9, CD63, and CD81), (H) with associated size and concentration profiles ( n = 9–10 at both timepoints). EV marker values at MI presentation were normalized to each patient’s own 3-month follow-up value. In (G), data are presented as group means ± SD. Statistical analysis: (A–C) Wilcoxon matched-pairs signed-rank test; (G) two-way ANOVA with Tukey’s post hoc test. ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001.

    Journal: iScience

    Article Title: Plasma extracellular vesicle modulate immune cell transcriptional responses following acute myocardial infarction

    doi: 10.1016/j.isci.2026.114665

    Figure Lengend Snippet: Characterization of plasma EV in MI patients EVs were isolated from the plasma of MI patients at hospital presentation and at 3-month follow-up. (A) EV-Array analysis of canonical EV-associated markers shows significant enrichment at MI presentation ( n = 17 patients paired at both timepoints). (B) EV-cell-associated markers were also enriched at presentation with MI. White in the heatmaps denotes the baseline (normalized to 1), corresponding to the 3-month follow-up value. (C) Total EV concentrations measured by NTA of SEC and ultracentrifugation-purified plasma EVs. (D and E) Spaghetti plots showing EV size and particle concentration profiles at the individual patient level across the two timepoints ( n = 19 patients paired at both timepoints). (E) Western blotting confirmed the presence of EV markers (CD9 and Syntenin-1), absence of cellular contaminants (GM130, ATP5A, and Histone H3), and depletion of the plasma Apo B. (F) TEM images confirmed typical cup-shaped EV morphology. Scale bars, 500 nm or 100 nm. (G and H) Single-particle interferometric reflectance imaging (NanoView) confirmed tetraspanin-positive EVs (CD9, CD63, and CD81), (H) with associated size and concentration profiles ( n = 9–10 at both timepoints). EV marker values at MI presentation were normalized to each patient’s own 3-month follow-up value. In (G), data are presented as group means ± SD. Statistical analysis: (A–C) Wilcoxon matched-pairs signed-rank test; (G) two-way ANOVA with Tukey’s post hoc test. ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001.

    Article Snippet: CD63 , Biorad , MCA2142; RRID: AB_324562.

    Techniques: Clinical Proteomics, Isolation, Purification, Concentration Assay, Western Blot, Single Particle, Imaging, Marker

    Enrichment of miRNA-320b in endothelial cell-derived EV following inflammatory stimulation HUVECs were cultured under control (black) or TNF-α-stimulated (red) conditions to model endothelial inflammation. (A) Total and viable cell counts at study endpoint confirm similar cell numbers across conditions. (B) Soluble VCAM-1 levels in supernatants were significantly increased following TNF-α stimulation, confirming proinflammatory activation. (C and D) Single-particle interferometric reflectance imaging (NanoView) detected CD9, CD63, and CD81-positive EVs in both conditions. Scale bars, 10 μm. (D) Total captured EV concentrations were significantly higher in TNF-α-stimulated cultures. (E) Average particle diameters of captured EVs did not differ significantly. (F) NTA showed elevated particle concentrations in EV preparations from TNF-α-treated HUVECs. (G) Size distribution profiles of EVs from control and TNF-α conditions. (H) EV counts were normalized to total and live cell numbers, confirming increased release under inflammatory stimulation. (I) Western blot analysis of HUVEC-derived EVs confirmed enrichment of canonical EV markers (TSG101, Syntenin-1, and CD9), absence of cellular contaminant GM130, and presence of VCAM-1 specifically in TNF-α-derived EVs. (J) TEM images showed characteristic EV morphology; scale bars, 1 μm or 500 nm. (K) RT-qPCR showed no change in HUVEC cellular miRNA-320b levels between conditions. (L) Significant enrichment of miRNA-320b was detected in EVs from TNF-α-stimulated HUVECs. miRNA expression was normalized to UniSp6 spike-in control, because endogenous controls (e.g., miR-103a-3p) were undetectable in EV samples. Data are presented as group means ± SD. N = 4 biological replicates per group. Statistical analysis: (B, F, L) unpaired Student’s t test; (D, H) two-way ANOVA with Tukey’s post hoc test. ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001.

    Journal: iScience

    Article Title: Plasma extracellular vesicle modulate immune cell transcriptional responses following acute myocardial infarction

    doi: 10.1016/j.isci.2026.114665

    Figure Lengend Snippet: Enrichment of miRNA-320b in endothelial cell-derived EV following inflammatory stimulation HUVECs were cultured under control (black) or TNF-α-stimulated (red) conditions to model endothelial inflammation. (A) Total and viable cell counts at study endpoint confirm similar cell numbers across conditions. (B) Soluble VCAM-1 levels in supernatants were significantly increased following TNF-α stimulation, confirming proinflammatory activation. (C and D) Single-particle interferometric reflectance imaging (NanoView) detected CD9, CD63, and CD81-positive EVs in both conditions. Scale bars, 10 μm. (D) Total captured EV concentrations were significantly higher in TNF-α-stimulated cultures. (E) Average particle diameters of captured EVs did not differ significantly. (F) NTA showed elevated particle concentrations in EV preparations from TNF-α-treated HUVECs. (G) Size distribution profiles of EVs from control and TNF-α conditions. (H) EV counts were normalized to total and live cell numbers, confirming increased release under inflammatory stimulation. (I) Western blot analysis of HUVEC-derived EVs confirmed enrichment of canonical EV markers (TSG101, Syntenin-1, and CD9), absence of cellular contaminant GM130, and presence of VCAM-1 specifically in TNF-α-derived EVs. (J) TEM images showed characteristic EV morphology; scale bars, 1 μm or 500 nm. (K) RT-qPCR showed no change in HUVEC cellular miRNA-320b levels between conditions. (L) Significant enrichment of miRNA-320b was detected in EVs from TNF-α-stimulated HUVECs. miRNA expression was normalized to UniSp6 spike-in control, because endogenous controls (e.g., miR-103a-3p) were undetectable in EV samples. Data are presented as group means ± SD. N = 4 biological replicates per group. Statistical analysis: (B, F, L) unpaired Student’s t test; (D, H) two-way ANOVA with Tukey’s post hoc test. ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001.

    Article Snippet: CD63 , Biorad , MCA2142; RRID: AB_324562.

    Techniques: Derivative Assay, Cell Culture, Control, Activation Assay, Single Particle, Imaging, Western Blot, Quantitative RT-PCR, Expressing